METTL1 inhibitor - STORM Therapeutics
Alternative Names: tRNA methyltransferase inhibitor - STORM TherapeuticsLatest Information Update: 28 Feb 2024
At a glance
- Originator Storm Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action METTL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Feb 2024 Pharmacodynamics data from preclinical studies in Cancer released by Storm Therapeutics
- 08 Dec 2023 METTL1 inhibitor - STORM Therapeutics is available for licensing as of 21 Dec 2023 (STORM therapeutics pipeline December 2023)
- 08 Dec 2023 Pharmacodynamics data from a preclinical studies in Cancer released by STORM Therapeutics